Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Additional Phase 3, Multicenter Study of Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury

NCT07722962 is registered in ClinicalTrials.gov with Kringle Pharma, Inc. as lead sponsor.

NCT NCT07722962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07722962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Additional Phase 3, Multicenter Study of Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury
Lead sponsor
Kringle Pharma, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
December 31, 2028
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury (sci)